The Nikkei average tumbled 4.80 percent to 37,919.55 while the broader Topix index closed 3.47 percent lower at 2,645.94.
Heranba Industries (30-09-2024)
Hi,
This photo was taken in the month of June’24 during my outside visit to the plant. The left side building is the new wing in GIDC Sarigam, Valsad, GJ.
Dont have any update if it operational yet or not and details about the other ongoing CAPEX
Disclosure: I’ve active position in the said scrip
Macrotech Developers Ltd leads losers in ‘A’ group (30-09-2024)
Sterling & Wilson Renewable Energy Ltd, Kaveri Seed Company Ltd, Shoppers Stop Ltd and Newgen Software Technologies Ltd are among the other losers in the BSE’s ‘A’ group today, 30 September 2024.
Mankind Pharma to raise up to ₹100,000 crore via NCDs and CPs, shares dip (30-09-2024)
Specific coupon rates, allotment dates, and maturity dates for the instruments yet to be determined
Mayank portfolio (30-09-2024)
added Thyrocare and exited from All e tech and wockhard.
Thyrocare- margin expection B2C business want to add krsnaa but due to its B2G dependence added thryocare.
All e tech is performing well but due to its current runup value went up and some how i want stay away from SME space for now.going to track it in future.
Wockhard exited due to the probablity of success in molecule is not very high
and i dont want to take that risk when i have better options.
cut some holding from supriya , neuland and added jubilant pharmova, lauras .On pharma i am trying to improve my understanding taking basket approach in it.
Nifty’s October returns positive on 8 out of 10 years; DIIs shine while seasonality adverse for FIIs (30-09-2024)
Nifty’s October performance over the past decade has been largely positive, with the index closing higher on eight occasions. Domestic institutional investors have been net buyers, while foreign institutional investors have often sold. Sectoral indices like Bank Nifty and Nifty Auto also showed strong gains during this period.
Mankind Pharma’s fund raising committee OKs to raise Rs 10,000 cr via NCDs & CP (30-09-2024)
The pharma major announced that its fund raising committee approved to raise funds through non-convertible debentures (NCDs) and commercial papers (CP) aggregating to Rs 10,000 crore in one or more tranches.